To this regard, a recent study has demonstrated that intravenous treatment with ascorbate induced clinical remission in a patient with AML carrying TET2 and WT1 mutations in separate clones, after failure of induction chemotherapy [15]. This evidence concerns the gene WT1 and acute myeloid leukemia.